A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Nidhi, Aditi
- The Crossroad between Intellectual Property and Clinical Trials: Balancing Incentives for Innovation with Access to Healthcare
Authors
1 Gujarat National Law University, Gandhinagar, Gujarat — 382 421, IN
Source
Journal of Intellectual Property Rights, Vol 28, No 4 (2023), Pagination: 284-292Abstract
Intellectual property (IP) is essential for encouraging innovation in the pharmaceutical business, particularly in clinical trials. However, IP can also limit access to healthcare by making drugs and treatments unaffordable for certain populations. The pharmaceutical industry relies heavily on intellectual property protections to incentivize innovation and support the development of new drugs. Moreover, clinical trials play an indispensable part in the medication development process, providing the evidence needed to support regulatory approval and marketing. The intersection of intellectual property and clinical trials raises important legal and ethical issues that need to be carefully considered. This article analyses the significance of intellectual property in the process of drug innovation, its impact on clinical trials, and the ways in which intellectual property might affect the accessibility and price of new treatments. This paper also explores the balance between incentivizing innovation through IP and ensuring access to healthcare, notably within the setting of clinical trials.
It examines the history of intellectual property laws in the pharmaceutical industry, how patents and exclusivity encourage innovation, and how these incentives affect healthcare access. The paper also discusses alternative models for incentivizing innovation, such as open-source drug development and prize-based systems. The article concludes that while intellectual property is vital to encourage innovation in the pharmaceutical business, it must be balanced with efforts to assure universal access to healthcare. We argue that policymakers and industry stakeholders must work together to develop policies and practices that promote innovation while ensuring that new drugs are accessible and affordable to all.
Keywords
Intellectual Property, Clinical Trials, Innovation, Access to Healthcare, Pharmaceutical Industry, Patents, Exclusivity, Open-Source Drug Development, Prize-Based Systems.References
- Rituparna M et. al., Essential medicines: An Indian perspective, Indian Journal of Community Medicine, 40 (4) (2015) 223-232.
- Rang H & Hill R, Drug Development: Introduction, Drug Discovery and Development, 2 (1) (2013) 203-209.
- Gurgula O, Strategic patenting by pharmaceutical companies – Should Competition Law Intervene? IIC - International Review of Intellectual Property and Competition Law, 51 (2020) 1062–1085.
- Kyle M K, Competition Law, Intellectual property and the pharmaceutical sector, Antitrust Law Journal, 81 (1) (2016) 1-36.
- Chatterjee A, Chilukuri S, Fleming E, Knepp A, Rathore S & Zabinski J, Real-world evidence: Driving a new drug-development paradigm in oncology, 24 July 2018, https://www.mckinsey.com/industries/life-sciences/our-insights/real-world-evidence-driving-a-new-drug-development-paradigm-in-oncology.
- Andanda P, Towards a paradigm shift in governing data access and related intellectual property rights in Big Data and health-related research, IIC - International Review of Intellectual Property and Competition Law, 50 (2019) 1052–1081.
- Chandra S & Bhattacharya S, Intellectual property rights: An overview and implications in pharmaceutical industry, Journal of Advanced Pharmaceutical Technology & Research, 2 (2) (2011) 88-93.
- Racherla U S, Historical evolution of India’s Patent Regime and its impact on innovation in the Indian pharmaceutical industry, Innovation, Economic Development, and Intellectual Property in India and China, (Springer, 2021).
- Robert P M & Nelson R R, On the complex economics of Patent Scope, Columbia Law Review, 90 (4) (1990) 839–916.
- Jeremy G & Scott P, Reform, regulation, and pharmaceuticals — The Kefauver–Harris Amendment, The New England Journal of Medicine, 367 (16) (2012) 1481.
- Mossinghoff G J, Overview of the Hatch-Waxman Act and its impact on the drug development process, Food and Drug Law Journal, 54 (1999) 187.
- Kesselheim A S & Darrow J J, Hatch-Waxman Turns 30: Do we need a re-designed approach for the modern era? Yale Journal of Health Policy, Law and Ethics, 15 (2015) 293.
- Garth B et. al., Development of the Generic Drug Industry in the US after the Hatch-Waxman Act of 1984, Acta Pharmaceutica Sinica B, 3 (5) (2013) 297-311.
- Van Norman, Gail, drugs, devices, and the FDA: Part 1: An overview of approval processes for drugs, JACC: Basic to Translational Science, 1 (3) (2016) 170-179.
- Sivanandan S, Jain K, Plakkal N et. al., Issues, challenges, and the way forward in conducting clinical trials among neonates: Investigators’ perspective, J Perinatol, 39 (Suppl 1) (2019) 20–30.
- Gupta H et. al., Patent protection strategies, Journal of Pharmacy and Bioallied Sciences, 2 (1) (2010) 2-7.
- Antoñanzas F, Juárez-Castelló C & Rodríguez-Ibeas R, Pharmaceutical patents, R&D incentives and access to new drugs: New ways of progress at the crossroad, Eur J Health Econ, 12 (2011) 393–395.
- Dominique G, Patents as an Incentive to Innovate, The Economics of the European Patent System: IP Policy for Innovation and Competition (Oxford, 2007; online edn, Oxford Academic) 2007.
- David E, Mehta A, Norris T, Singh N & Tramontin T, New frontiers in Pharma R&D investment, 1 February 2010, https://www.mckinsey.com/industries/life-sciences/our-insights/new-frontiers-in-pharma-r-and-38d-investment.
- Gaessler F & Wagner S, Patents, Data Exclusivity, and the Development of New Drugs, Rationality and Competition Discussion Paper Series 176, CRC TRR 190, Rationality and Competition, (2019) 1-50.
- Heidi W, How do patents affect research investments? Annual Review of Economics, 9 (2017) 441.
- Dwivedi S et. al., Intellectual property rights in healthcare: An overview, Biotechnology in Healthcare, 2022, 259-266.
- Walsh K, Wallace A, Pavis M et. al., Intellectual property rights and access in crisis, IIC - International Review of Intellectual Property and Competition Law, 52 (2021) 379–416.
- Gupta U, Informed consent in clinical research: Revisiting few concepts and areas, Perspectives in Clinical Research, 4 (1) (2013) 26-32.
- Fogel D, Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review, Contemporary Clinical Trials Communications, 11 (2018) 156-164.
- Thomas F & Powers J, Biomarkers and surrogate endpoints in clinical trials, Statistics in Medicine, 31 (25) (2012) 2973.
- Schievink B, Heerspink H L, et.al., The use of surrogate endpoints in regulating medicines for cardio-renal disease: Opinions of stakeholders, Opinions on Surrogate Endpoint Use, 9 (2014) 1-7.
- Bekker G, et. al., Advancing global health and strengthening the HIV response in the era of the sustainable development goals: The international AIDS society—Lancet Commission, Lancet, 392 (10144) (2003) 312-358.
- Morgan S G, Bathula H S & Moon S, Pricing of pharmaceuticals is becoming a major challenge for health systems, BMJ, 368 (2020) 1-4.
- Devarajan S & Das J, improving access to drugs: Fitting the solution to the problem, World Blank blog; https://blogs.worldbank.org/africacan/improving-access-to-drugs-fitting-the-solution-to-the-problem.
- Tenni B, Moir H V J, Townsend B, et. al., What is the impact of intellectual property rules on access to medicines? A systematic review, Global Health, 18 (2022) 40.
- Eduardo U & Ramani S, Access to medicines after TRIPS: Is compulsory licensing an effective mechanism to lower drug prices? A review of the existing evidence, Journal of International Business Policy, 3 (4) (2020) 367-384.
- Islam Md, et. al., Impacts of intellectual property provisions in trade treaties on access to medicine in low- and middle-income countries: A systematic review, Globalization and Health, 2019, 15.
- Rajkumar S, The high cost of prescription drugs: Causes and solutions, Blood Cancer Journal, 10 (6) (2020).
- Scheckel C J, Rajkumar V S, Drug importation: Limitations of current proposals and opportunities for improvement, Blood Cancer Journal, 11 (2021) 132.
- Chen Y, Monnard A & Silva J S da, An inflection point for biosimilars, 7 June 2021, https://www.mckinsey.com/industries/life-sciences/our-insights/an-inflection-point-for-biosimilars.
- Mariateresa M & Zoboli L, The intersection between Intellectual Property and Antitrust Law, in Irene Calboli, and Maria LillàMontagnani (eds), Handbook of Intellectual Property Research: Lenses, Methods, and Perspectives (Oxford, 2021; online edn, Oxford Academic) 2021.
- Inan O T, Tenaerts P, Prindiville S A, et. al., Digitizing clinical trials, Digit Med, 3(1) (2020) 1-7.
- Veluswamy S K & Babu A S, Clinical trial registration: What do we need to know? Indian Journal of Respiratory Care, 4 (2015) 618.
- Pallmann P, Bedding A W, Choodari-Oskooei B, et. al., Adaptive designs in clinical trials: Why use them, and how to run and report them, BMC Med, 16 (2018) 29.
- Bhatt A, Conducting real-world evidence studies in India, Perspectives in Clinical Research, 10 (2) (2019) 51-56.
- Joseph R K & Abrol D, National IPR Policy of India and Innovation, Institute for Studies in Industrial Development, 1 (2016) 1-9.
- Pandey M, National IPR Policy: An analysis, IP and Legal Filings, 2023.
- Mishr, S, Performance of the Indian pharmaceutical industry in post-TRIPS period: A firm level analysis, International Review of Business Research Papers, 5 (6) (2009), 148-160.
- Julian I, The World’s Pharmacy: India’s generic drug industry, Global Business Reports, 2020.
- India Pharma Propelling access and acceptance, realising true potential, McKinsey & Company, 2020, 10-38.
- Sahu S K, Globalization, WTO, and the Indian pharmaceutical industry, Asian Affairs, 41(4) (2014) 172–202.
- Sugumaran G, Open-source drug discovery - redefining IPR through open-source innovations, Current Science, 102 (2012) 1637-1639.
- Adams C P & Brantner V V, Estimating the cost of new drug development: Is it really $802 million? Health Affairs, 25 (2) (2006) 420-428.
- Agitha T G, Alternative incentive models delinking R&D costs from pharmaceutical product price, Journal of Intellectual Property Rights, 18 (2013) 491-498.
- Muigai A W T, Expanding global access to genetic therapies, Nat Biotechnol, 40 (2022) 20–21.
- Simpkin V, Renwick M, Kelly R. et. al., Incentivising innovation in antibiotic drug discovery and development: Progress, challenges and next steps, Journal of Antibiotics, 70 (2017) 1087–1096.
- Luciano K, Opportunities and challenges in the use of innovation prizes as a Government Policy Instrument, Minerva, 50 (2) (2012) 191–96.
- Christopher K & Young A, Promoting innovation in healthcare, Future Healthcare Journal, 4 (2) (2017) 121-125.
- Harold L, Economic incentives to promote innovation in healthcare delivery, Clinical Orthopaedics and Related Research, 467 (10) (2009) 2497-2505.
- Kaur A & Chaturvedi R, Compulsory licensing of drugs and pharmaceuticals: Issues and dilemma, Journal of Intellectual Property Rights, 20 (2015) 279-287.
- Artificial Intelligence and Blockchain: A Breakthrough Collaboration in IP Law
Authors
1 School of Law, Bennett University, Greater Noida -201 310, IN
2 School of Law, Mahindra University, Hyderabad - 500 043, IN
Source
Journal of Intellectual Property Rights, Vol 28, No 5 (2023), Pagination: 383-391Abstract
Artificial Intelligence and blockchain technology now influence the intellectual property environment. For example, machine learning is now regularly used in trademark and patent searches in IP databases. Machine learning implementations in different IP areas, including patent tracking, copyright evaluation, and trademark comparisons, can now be seen more often. A vast range of LP notary implementations are proposed using blockchain technologies, and new networks emerge, using both AIs and blockchains to build new IP communities. The growth of such technology in LPP is mainly driven by the IT industries, particularly technology entrepreneurs. In the context of the non-registered IP rights such as copyright (which under the Berne Convention for the Protection of Literary and Artistic Works and in many jurisdictions is not registrable) and unregistered design rights, blockchain technology can play an important role, too, because it can prove its conception, use and qualification (for example the countries where the design was first marketed and originality). Uploading the author or creator’s work and design data into a blockchain would produce a time-stamped record and solid proof of originality.So, IPO has laid the groundwork for the technology’s fusion into the IP ecosystem. Several other possible uses include ledger management, the creation of a monitoring authority to track the use of IP properties in the market and commercialization for investors via a bidding system. It will provide innovators with a centralized, government-backed market to attract investors and technology titans.Keywords
Artificial Intelligence, Blockchain, Copyright, Design, Patent, Smart Contract, IPR Ledger, Distributed Ledger TechnologyReferences
- Two New Bills in Congress Offer Clarity for Blockchain Tokens and Crypto Exchanges, In The News, 2020, https://congressionalblockchaincaucus-schweikert.house.gov/media/in-the-news/two-new-bills-congress-offer-clarity-blockchain-tokens-and-crypto-exchanges.
- Banerjee A, Blockchain with IoT: Applications and use cases for a new paradigm of supply chain driving efficiency and cost, Advances in Computers, 115 (2019) 259-292.
- Weller C, Elon Musk doubles down on universal basic income: ‘It’s going to be necessary’, businessinsider.in/elon-musk-doubles-down-on-universal-basic-income-its.
- Ryan J K, Stephen Hawking sets out to control Artificial Intelligence-Before it controls us, https://www.inc.com/kevin-j-ryan/stephen-hawking-artificial-intelligence-research-center.html.
- Livni E, Your next lawyer could be a machine, World Economic Forum, https://www.weforum.org/agenda/2017/02/machines-could-soon-replace-lawyers.
- Beck S, The Future of Law, The Am. Lawyer, An A.L.M. Publication, 2014, 1-6.
- Spangler S, Disruptive Innovation in the Legal Services Market: Is Real change coming to the business of law, or will the status quo reign? A.B.A. Annual Meeting, http://www.americanbar.org/content/dam/aba/administrative/litigation/materials/2014_aba_annual/written-materials/disruptive_innovation.authcheckdam.pdf.
- Matthew S U, Regulating Artificial Intelligence systems: Risks, challenges, competencies, and strategies, Harvard Journal of Law and Technology, 29 (2016) 353-398.
- Katz M D, Quantitative legal prediction-or-how I learned to stop worrying and start preparing for the data-driven future of the legal services industry, EMORY L.J., 62 (2013) 909-966.
- Maloof M, Artificial Intelligence: An introduction, Georgetown U, http://people.cs.georgetown.edu/~maloof/ cosc270.s15/cosc270-intro-handout.pdf.
- Mills M, Artificial Intelligence in Law: The state of play, Thompson Reuters, 2016 https://britishlegalitforum.com/wp-content/uploads/2016/12/Keynote-Mills-AI-in-Law-State-of-Play-2016.pdf.
- Mills M, Law firm leaders shark tank: Micheal Mills of Neota Logic talks AI, Thompson Reuters Legal Executive Institute, 2016 http://legalexecutiveinstitute.com/sharktank-neota-logic/.
- Russell S, Artificial Intelligence- A Modern Approach (Dorling Kindersley, New Delhi), 2009, 29-300.
- Banu V S, Blockchain technology, International Journal of Engineering Research & Technology, 7 (11) (2019) 1-2.
- Sawada Y, Distributed Ledger Technology and Digital Assets: Policy and Regulatory Challenges in Asia (Asian Development Bank, Philippines), 2019, 1-51.
- Shairwal S, Blockchain & IPR: a breakthrough collaboration, https://www.lexology.com/library/detail.aspx?g=ac54cb4d-9b47-46ad-81a4-55ef28bd0f96.
- Wegrzyn E K, Types of blockchain: Public, private, or something in between, https://www.foley.com/en/insights/publications/2021/08/types-of-blockchain-public-private-between.
- Wen P H, Babu S L, et al., Blockchain for decentralization of internet: Prospects, trends, and challenges, Cluster Comput, 24 (2021) 2841-2866.
- Iansiti M, The Truth About Blockchain, Harvard Business Review, 95 (1) (2017) 2701-2709.
- Rosslee N, Artificial Intelligence and Blockchain | How will these impact IP law? 2017, https://www.lexology.com/ library/detail.aspx?g=2dddeaa3-b0e9-466b-acf3-d8ab098291fb.
- Jayachandran P, The difference between public and private Blockchain, 2017, I.B.M. Supply Chain and Blockchain Blog; https://www.ibm.com/blogs/blockchain/2017/05/the-difference-between-public-and-private-blockchain/.
- https://www.economist.com/leaders/2015/10/31/the-trust-machine (accessed on 21 May 2022).
- Andreseen M, What is Blockchain Technology? Coindesk https://www.coindesk.com/learn/blockchain-101/what-is-blockchain-technology.
- Singh S A, How combining blockchain technology and AI could benefit patent analysis, https://www.lexology.com/ library/detail.aspx?g=82c74b27-edf5-4ec9-bcee-c549a2f96cba.
- Lone A H, Applicability of blockchain smart contracts in securing internet and IOT: A systematic literature review, Computer Science Review, 39 (2021) 100360-100369.
- Rehman M H U & Salah K, Blockchain for AI: Review and open research challenges, IEEE Access, 7 (2019) 10127-10149.
- Prasad S, The future of Blockchain in Intellectual Property, 2021 https://www.automation.com/en-us/articles/january-2021/the-future-of-blockchain-in-intellectual-property.
- Pandya S, Blockchain and IPR | Disruption & amelioration, International Journal of Advanced Legal Research, 2021, 1-11.
- Finck M, Copyright Law on Blockchains: Between new forms of rights administration and Digital Rights Management 2.0., International Review of Intellectual Property and Competition Law, 50 (2019) 77-108.
- Patent Prosecution Highway (PPH) - Fast Track Examination of Applications, https://www.uspto.gov/patents/basics/ international-protection/patent-prosecution-highway-pph-fast-track.
- Liang Q, Can blockchain link the future?, Digital Communications and Networks, 8 (5) (2022) 687-694.
- The admissibility of Blockchain as Digital Evidence, Concord Law School, https://www.concordlawschool.edu/ blog/news/admissibility-blockchain-digital-evidence/.
- Kim L, China patent: Courts respond positively to Blockchain evidence, https://www.managingip.com/article/2a5bssmgulfpv353htybk/china-patent-courts-respond-positively-to-blockchain-evidence.
- Brunner R, China: Chinese Court is first to accept Blockchain as means of evidence, https://www.mondaq.com/china/copyright/723594/chinese-court-is-first-to-accept-blockchain-as-means-of-evidence.
- Sawada Y, Distributed Ledger Technology And Digital Assets Policy And Regulatory Challenges In Asia (Asian Development Bank, Phillipines), 2019, 1-63.
- Act, Uniform Electronic Transactions Act, 1999, United States, 1999.
- Act, The Information Technology Act, 2000, Government of India, 2000.
- Section 10A, Information Technology Act, 2000, Government of India, 2000.
- Jaipuriar A, A new digital order– Unveiling the interplay of Law & Blockchain Technology - Part B | Blockchain Technology & Legal Framework: Analysing India’s Blockchain Preparedness, 2020, https://www.mondaq.com/ india/fin-tech/975778/a-new-digital-order-unveiling-the-interplay-of-law-blockchain-technology--part-b-blockchain-technology-legal-framework-analysing-india39s-blockchain-preparednes.
- NITI Aayog, Blockchain: The India Strategy, 2020, 31-32, https://niti.gov.in/sites/default/files/202001/Blockchain_The_India_Strategy_Part_I.pdf.
- Reyna A, On Blockchain and its integration with IoT: Challenges and opportunities, Future Generation Computer Systems, 88 (2018) 173-190.
- http://bwlegalworld.businessworld.in/article/Chaining-Intellectual-Property-Rights-To-Blockchain/17-05-2022-428409/.
- Shubhani A, Blockchain 2.0: Smart contracts, Advances in Compters, 121 (2021) 301-322.
- Raskin M, The law and legality of smart contracts, Georgetown Law Technology Review, 1 (2) (2017) 305-326.
- Blockchain and Intellectual Property Rights Protection Technology, https://originstamp.com/blog/blockchain-and-intellectual-property-rights-protection-technology/.
- Stark J, Making sense of blockchain smart contracts, Coindesk, 2016, https://www.coindesk.com/making-sense-smart-contracts.
- Khan S N, Loukil F, Ghedira-Guegan C, et. al., Blockchain smart contracts: Applications, challenges, and future trends, Peer-to-Peer Netw. Appl., 14 (2021) 2901-2925.
- Nakamoto S, Bitcoin: A peer-to-peer electronic cash system, Satoshi Nakamoto Institute, 2008, https://nakamotoinstitute.org/bitcoin/.
- Atlam H F, Blockchain with internet of things: Benefits, challenges, and future directions, International Journal of Intelligent Systems and Applications, 10 (6) (2018) 40–48.
- Yang F, Industry 4.0, A revolution that requires technology and national strategies, Complex & Intelligent Systems, 7 (2021) 1311-1325.
- Vijai C, URR Blockchain and Distributed Ledger Technology (DLT): The future of accounting, Journal of Human Kinetics, 58 (2021), 320-323. 52 Sedlmeir J, Lautenschlager J, Fridgen G, et. al., The transparency challenge of Blockchain in organizations, Electron Markets, 2022, https://doi.org/10.1007/s12525-022-00536-0.
- Baker S, Disclosure as a strategy in the patent race, The Journal of Law & Economics, 48(1) (2005) 173-194.